• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • Global health

    Drug prices soar after pharma giants GSK and Sanofi exit Nigeria

    Nigerians struggle to buy their prescribed medicines due to continuous price jumps caused by the country’s high inflation rate, weak naira, high import duties, and a deluge of exits by multinationals such as GSK and Sanofi.

    By Pelumi Salako // 04 April 2024

    Last October, Idoma Prince visited a pharmacy in Nigeria’s capital city of Abuja to replace his old inhaler but he returned home empty-handed.

    The 24-year-old user interface designer was shocked after he was told the cost of a Ventolin inhaler, which he uses for his asthma, was now 8,500 Nigerian naira ($5.34). He returned home with the thoughts of the shocking price looming in his mind. Just a few months before, he had bought the same product for 3,500 naira ($2.46).

    “I wasn’t prepared for that [price] at all so I had to delay getting it till I had enough money on me. This January I went to get [it] again and I saw that the price had gone up to 10,000 naira ($7.02) for one inhaler,” he told Devex.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in

    More reading:

    ► The AU plans to pool resources to unify $50B pharma market (Pro)

    ► Big Pharma slammed for executive payouts that nearly match R&D budget

    ► African Development Bank sets up foundation to boost pharma sector

    • Global Health
    • Social/Inclusive Development
    • Trade & Policy
    • Private Sector
    • GSK
    • Sanofi
    • Nigeria
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Pelumi Salako

      Pelumi Salako

      Pelumi Salako is a Nigerian journalist covering culture, technology, inclusive economies, and development. His works have appeared in Al Jazeera, The Guardian, the Thomson Reuters Foundation, NPR, Foreign Policy, and elsewhere. He holds a B.A. in History and International Studies from the University of Ilorin.

    Search for articles

    Related Stories

    Global HealthWHO adopts new global strategy on traditional medicine

    WHO adopts new global strategy on traditional medicine

    Global HealthWe know how to treat anemia. So why is it still so common?

    We know how to treat anemia. So why is it still so common?

    Global HealthNoncommunicable diseases: A policy success but implementation failure

    Noncommunicable diseases: A policy success but implementation failure

    Devex Pro InsiderDevex Pro Insider: USAID's 'final' gut punch, and ahoy State Department mateys

    Devex Pro Insider: USAID's 'final' gut punch, and ahoy State Department mateys

    Most Read

    • 1
      Opinion: How climate philanthropy can solve its innovation challenge
    • 2
      The legal case threatening to upend philanthropy's DEI efforts
    • 3
      Why most of the UK's aid budget rise cannot be spent on frontline aid
    • 4
      Opinion: It’s time to take locally led development from talk to action
    • 5
      2024 US foreign affairs funding bill a 'slow-motion gut punch'
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement